{"filing":{"accession_number":"0001628280-26-051045","cik":"0001447362","ticker":"CSTL","company_name":"CASTLE BIOSCIENCES INC","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"cstl-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1447362/000162828026051045/cstl-20260730.htm"},"events":[{"id":22682,"run_id":20519,"accession_number":"0001628280-26-051045","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Castle Biosciences issued a press release on July 30, 2026, announcing Q2 2026 financial results with revenue of $103.5 million and a net loss of $2.1 million, while raising full-year 2026 revenue guidance to $365–375 million from $345–355 million and signaling expectations of positive Adjusted EBITDA for the remainder of 2026.","company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22696,"accession_number":"0001628280-26-051045","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Castle Biosciences issued a press release on July 30, 2026, announcing its financial results for the second quarter ended June 30, 2026, disclosing Q2 2026 revenue of $103.5 million, net loss of $2.1 million, and raising full-year 2026 revenue guidance to $365-375 million from $345-355 million. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:17:27.269343+00:00","company_name":"","ticker":null,"filing_date":""},{"id":22697,"accession_number":"0001628280-26-051045","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references a slide presentation (Exhibit 99.2) made available on July 30, 2026, but the substantive content provided is Castle Biosciences' Q2 2026 earnings release (Exhibit 99.1), which reports quarterly financial results including $103.5 million in Q2 revenue, raised full-year guidance to $365-375 million, and expectations of positive Adjusted EBITDA for Q3, Q4, and full-year 2026. This is a standard earnings release disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:17:27.269343+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22696,"accession_number":"0001628280-26-051045","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Castle Biosciences issued a press release on July 30, 2026, announcing its financial results for the second quarter ended June 30, 2026, disclosing Q2 2026 revenue of $103.5 million, net loss of $2.1 million, and raising full-year 2026 revenue guidance to $365-375 million from $345-355 million. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:17:27.269343+00:00","company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","filing_date":"2026-07-30"},{"id":22697,"accession_number":"0001628280-26-051045","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references a slide presentation (Exhibit 99.2) made available on July 30, 2026, but the substantive content provided is Castle Biosciences' Q2 2026 earnings release (Exhibit 99.1), which reports quarterly financial results including $103.5 million in Q2 revenue, raised full-year guidance to $365-375 million, and expectations of positive Adjusted EBITDA for Q3, Q4, and full-year 2026. This is a standard earnings release disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:17:27.269343+00:00","company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","filing_date":"2026-07-30"}]}